Editorial

Charles Oo; Jui Chen Tsai; H. Danny Kao

doi:10.1016/j.drudis.2015.03.013

Editorial

Charles Oo, Jui Chen Tsai, H. Danny Kao

School of Pharmacy

Research output: Contribution to journal › Editorial › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	645-647
Number of pages	3
Journal	Drug Discovery Today
Volume	20
Issue number	6
DOIs	https://doi.org/10.1016/j.drudis.2015.03.013
Publication status	Published - 2015

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2015.03.013

Cite this

@article{e830adc5ec944f12b273236c371c4332,

title = "Editorial",

author = "Charles Oo and Tsai, {Jui Chen} and Kao, {H. Danny}",

note = "Funding Information: H. Danny Kao received his B.Sc. in Pharmacy from the National Taiwan University, M.S. from St. John's University, a Ph.D. from the University of Kentucky, and J.D. from the Touro College, New York. He is a registered patent attorney, a member of the Regulatory Working Group of Cross Company Abuse Liability Consortium, and has been awarded a fellowship from the Pharmaceutical Research and Manufacturers of America. He has an expertise in opioid drug formulations and delivery systems, and has more than 20 issued and pending patents. He currently works as the chief IP counsel and senior vice president of Relmada Therapeutics Inc, and has previously worked for Endo and DuPont Pharma. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2015",

doi = "10.1016/j.drudis.2015.03.013",

language = "English",

volume = "20",

pages = "645--647",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Editorial

AU - Oo, Charles

AU - Tsai, Jui Chen

AU - Kao, H. Danny

N1 - Funding Information: H. Danny Kao received his B.Sc. in Pharmacy from the National Taiwan University, M.S. from St. John's University, a Ph.D. from the University of Kentucky, and J.D. from the Touro College, New York. He is a registered patent attorney, a member of the Regulatory Working Group of Cross Company Abuse Liability Consortium, and has been awarded a fellowship from the Pharmaceutical Research and Manufacturers of America. He has an expertise in opioid drug formulations and delivery systems, and has more than 20 issued and pending patents. He currently works as the chief IP counsel and senior vice president of Relmada Therapeutics Inc, and has previously worked for Endo and DuPont Pharma. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84934988709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934988709&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2015.03.013

DO - 10.1016/j.drudis.2015.03.013

M3 - Editorial

C2 - 25835226

AN - SCOPUS:84934988709

SN - 1359-6446

VL - 20

SP - 645

EP - 647

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 6

ER -

Editorial

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this